Advertisement
NUVL Forex Aktualności
Nuvalent Stock Climbs 39% On $10.6 Bln Takeover Deal With GSK
Shares of Nuvalent, Inc. were surging around 39 percent in the pre-market activity on the Nasdaq, after the clinical-stage biopharma company focused on cancer therapies agreed to be acquired by British drug major GSK plc, in a deal valued at $10.6 billion or 8.0 billion pounds. Further, GSK maintained its 2026 guidance range of 7 percent to 9 percent growth in core operating profit and core EPS.
RTTNews
|
94 dni temu
Nuvalent Promotes Henry Pelish To Chief Scientific Officer
Biopharmaceutical company Nuvalent, Inc. (NUVL) announced Thursday that Henry Pelish has been promoted to Chief Scientific Officer. In this role, Pelish will continue to oversee discovery and early-stage development activities. He currently serves as Senior Vice President, Drug Discovery.
RTTNews
|
792 dni temu
